Results 1 to 10 of about 5,114,489 (264)
Frontiers in Pharmacology, 2023 Aims: Ferroptosis plays important roles in tumorigenesis and cancer therapy. Zoledronic acid is known to inhibit the activity of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
Tianhao Ren +10 more
doaj +2 more sources
How zoledronic acid improves osteoporosis by acting on osteoclasts
Frontiers in Pharmacology, 2022 Osteoporosis is called a silent disease, because it is difficult to detect until comprehensive examinations for osteoporosis are performed or osteoporotic fractures occur.
Biao Wang +4 more
doaj +2 more sources
Journal of Orthopaedic Surgery, 2021 Objectives: Both Zoledronic acid and denosumab have been utilized in neo-adjuvant setting for facilitating surgery and downsizing the lesion in Giant cell tumor (GCT).
Himanshu Kanwat +5 more
doaj +2 more sources
Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog [PDF]
Prostate Cancer, 2011 Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period ...
Anoop Kapoor +3 more
doaj +3 more sources
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
Journal of Bone Oncology, 2014 Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases.
Maria Wilke +8 more
doaj +2 more sources
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
JBMR Plus, 2020 Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patients exhibit a variable sensitivity to zoledronic acid; the underlying explanation for this remains unclear.
Anaïs M J Møller +5 more
doaj +2 more sources
Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment [PDF]
Scientific Reports, 2020 Zoledronic acid (ZOL) is a third generation bisphosphonate which can be used as a drug for the treatment of osteoporosis and metastasis. In this study, graphene oxide (GO) is conjugated with ZOL, and the nanostructured material is evaluated in terms ...
Gökçen Boran +4 more
openalex +2 more sources
Frontiers in Pharmacology, 2020 ObjectiveThis study aims to estimate the cost-effectiveness of yearly intravenous zoledronic acid treatment versus weekly oral alendronate for postmenopausal osteoporotic women in China.MethodsWe used a Markov microsimulation model to compare the cost ...
Ruxu You +8 more
doaj +2 more sources
A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid [PDF]
Science Advances, 2020 Combining BMP-2 and zoledronic acid is a recipe for creating “synthetic autologous bone” to treat large bone defects. Bone morphogenic proteins (BMPs) are the only true osteoinductive molecules.
Deepak Raina +7 more
openalex +2 more sources
Zoledronic acid in breast cancer: latest findings and interpretations [PDF]
Therapeutic Advances in Medical Oncology, 2011 The intravenous nitrogen-containing bisphosphonate zoledronic acid has been shown to block multiple steps in tumor metastasis (e.g. angiogenesis, invasion, adhesion, proliferation) in preclinical and translational studies.
Michael Gnant
doaj +2 more sources